Sermorelin
PeptideThe medical score (52) is lower than the community score (65) because clinical RCT data for off-label applications are limited [s4, s6], while community reports place greater weight on subjectively positive effects and describe outcomes that are difficult to objectively quantify clinically, such as "better sleep" or "more energy" [c1, c2].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Sermorelin stimulates endogenous growth hormone release via GHRH receptors — a more physiological approach than direct GH administration, but clinical evidence for off-label uses like anti-aging or body composition is largely absent. Its FDA approval was diagnostic only and voluntarily withdrawn in 2008; no EMA or German approval exists. Community users report improved sleep and recovery but increasingly view sermorelin as less potent than CJC-1295/Ipamorelin stacks. Rare but serious autoimmune-type reactions have been reported — medical supervision with IGF-1 monitoring is non-negotiable for any use.
Description
Synthetic GHRH analogue (amino acids 1–29) that stimulates endogenous growth hormone release from the pituitary gland [s2, s3].
Sermorelin is a synthetic peptide containing the first 29 amino acids of natural growth hormone-releasing hormone (GHRH) and fully replicating its biological activity [s2, s5]. It was originally developed as a diagnostic agent for assessing pituitary growth hormone reserve and received FDA approval in 1997 under the brand name Geref [s3]. Unlike direct administration of recombinant human growth hormone (rhGH), sermorelin stimulates endogenous GH production and secretion from the pituitary gland [s2]. This mechanism preserves the natural hypothalamic-pituitary feedback regulation and prevents uncontrolled GH overexposure [s5]. Following voluntary market withdrawal by the manufacturer in 2008, sermorelin is available in the USA only through compounding pharmacies [s1, s3]. Clinical studies demonstrate increases in IGF-1 levels as well as improvements in body composition and sleep quality [s4, s6]. In the biohacking community, sermorelin is frequently discussed as a "mild" and "more natural" GHRH analogue compared to CJC-1295 or exogenous rhGH, although robust RCT data for off-label applications such as anti-aging or body composition are limited [s4, s6, s7]. Use in the DACH region without a medical prescription is not legally permissible. Responsible use requires medical supervision, baseline laboratory values (IGF-1, GH stimulation test), and regular follow-up monitoring [s7].
Legal Status (DE)
In Germany, Austria, and Switzerland, sermorelin is not approved as a finished medicinal product. It is subject to the Medicinal Products Act (AMG) and is prescription-only in accordance with § 48 AMG. Sale without a medical prescription as a "research chemical" is legally ambiguous. The FDA approval (Geref) was voluntarily withdrawn in 2008; no EMA approval exists. Compounding in Germany is not permitted in the manner practised in the USA [s1, s3].
Mechanism of Action
Sermorelin contains the 29 N-terminal amino acids of endogenous GHRH (somatoliberin) and possesses the full biological activity of the parent molecule [s2, s5]. Following subcutaneous injection, sermorelin binds to GHRH receptors (GHRHR) on somatotrophs in the anterior pituitary gland [s2, s5]. Receptor activation triggers an intracellular signalling cascade: activation of adenylate cyclase → increase in cAMP → activation of protein kinase A → phosphorylation of transcription factors → gene expression and secretion of GH [s5]. This process is self-limiting, as the physiological feedback mechanisms (somatostatin inhibition, IGF-1 negative feedback) remain intact [s2, s5]. The released GH stimulates hepatic synthesis of insulin-like growth factor 1 (IGF-1), which mediates the anabolic, lipolytic, and mitogenic effects of GH [s4, s6]. Because sermorelin stimulates endogenous pituitary production rather than supplying exogenous GH, the risk of GH overexposure is regulated by somatostatin counter-regulation [s2]. Sermorelin acts preferentially at night, consistent with the natural pulsatility of GH secretion during deep sleep [s7, s8].
Dosing
Wachstumshormonmangel (adult-onset, therapeutisch)
- Dose
- 200–300 mcg
- Frequency
- 1× täglich subkutan
- Route
- injektion-subkutan
- Duration
- 3–6 Monate, dann Reevaluation
- Timing
- Shortly before bedtime (mimics physiological GH pulsatility)
- With food
- optional
Diagnostische GH-Stimulation
- Dose
- 1 mcg/kg body weight (i.v., clinical setting)
- Frequency
- Einmalig
- Route
- oral
- Duration
- Einmalanwendung
- Timing
- Morning fasted, under medical supervision
- With food
- vermeiden
No officially established upper limit for therapeutic applications in Germany, as no approval exists. Typical clinical practice in studies: max. 0.3 mg/day subcutaneously [s7, s8]. Higher doses increase the risk of injection site reactions and non-physiological GH stimulation.
Use only under medical supervision with regular IGF-1 monitoring. Sublingual forms (troches) are available, but with unclear bioavailability and no clinical validation [s7]. Injection sites should be rotated (abdomen, thigh, upper arm) [s8].
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Injektionsstellenreaktionen (Schmerz, Rötung, Schwellung, Juckreiz) Most commonly reported side effect with subcutaneous administration; can be minimized by correct injection technique and site rotation [s9, s10]. | häufig | leicht |
| Kopfschmerzen Documented in clinical reports during i.v. diagnostic use and subcutaneous therapy [s9]. | gelegentlich | leicht |
| Flush (Gesichtsrötung, Hitzegefühl) Common with intravenous administration as a diagnostic agent, less frequent with subcutaneous therapy [s9]. | gelegentlich | leicht |
| Übelkeit Documented with i.v. administration; occasionally reported with s.c. therapy [s9]. | gelegentlich | leicht |
| Auto-immune allergische Reaktionen (Urtikaria, Atemnot, Gesichtsschwellung) Reported in individual cases and community reports, including preparations from compounding pharmacies [c1]. Immediate discontinuation of therapy required. | selten | schwer |
| Schwindel Documented in clinical descriptions of therapeutic use [s10]. | gelegentlich | leicht |
| Brustenge (Tightness in the chest) Reported with i.v. diagnostic use [s9]. | selten | moderat |
| Verstärkter Hunger (bei kombinierten GHRP-Stacks) Not directly evidenced by sermorelin monotherapy, but documented with GHRP combinations (e.g., GHRP-2) [c3]. | theoretisch | leicht |
Contraindications
Interactions
Synergistic
Sermorelin stimulates pituitary GH release via GHRH receptors, while ipamorelin as a selective ghrelin receptor agonist (GHS-R) activates a complementary, synergistic signaling pathway. Combined use may result in markedly enhanced pulsatile GH secretion without substantially increasing cortisol release.
No qualified PubMed primary article with PMID found for the specific mechanism L-arginine → somatostatin inhibition → GH increase in the available search results. Gap remains open. Mechanism is established in general endocrinology textbooks (e.g., via NO synthase pathway), but no citable PMID available.
No qualified PubMed primary article found for the mechanism ashwagandha → cortisol reduction → GH/somatostatin axis in the available search results. Gap remains open.
L-glutamine is discussed as a supplementary amino acid to support GH release in combination with sermorelin. The effect is moderate and complements sermorelin-mediated stimulation.
Caution
Sigalos & Pastuszak 2018 (PMID 28431257) covers MK-677 pharmacology. A specific PubMed article on GHS-R desensitization/non-pulsatile GH stimulation by MK-677 was not retrievable with remaining search capacity. s19 entered as provisional source.
Hexarelin is a potent GHS-R agonist with additional activation of cardiovascular CD36 receptors and stronger stimulation of the ACTH/cortisol axis compared to more selective secretagogues. Combination with sermorelin may lead to excessive GH secretion as well as undesirable activation of the stress hormone axis; caution is therefore advised.
Studies
Tier A — High Evidence
Tier B — Moderate Evidence
Community Evidence
Top reported benefits
- Improved sleep quality and sleep depth
- Increased recovery rate after training
- Measurable IGF-1 increase on blood tests
- Body fat reduction and lean mass gain with prolonged use
- Increased energy and general well-being
Top reported issues
- Injection site reactions (redness, swelling, pruritus)
- Disappointment over lesser efficacy compared to CJC-1295/Ipamorelin stack
- High cost of compounding preparations
- Uncertainty about product quality from non-prescription sources
Isolated cases of autoimmune-like reactions (urticaria, dyspnoea) have been reported, including with prescription compounding preparations [c1]. Efficacy compared to newer GHRH analogues (CJC-1295 with DAC) is controversially discussed in the community; sermorelin is considered less potent [c2, c3]. Community data are limited (<40 analysed threads), as sermorelin is increasingly being replaced by other peptides.
Scientific Sources
- Sermorelin FDA Approved? (The Real Regulatory Truth)
TrimRX Medical Team (2026). TrimRX BlogCLink - Is Sermorelin Safe? Benefits, Risks, & What to Know
Eden Health Editorial (2025). Eden Health BlogCLink - Sermorelin (injection route) – Side Effects & Dosage
Mayo Clinic Staff (2024). Mayo Clinic Drug InformationBLink - Sermorelin vs. CJC-1295 vs. Ipamorelin – GHRH/GHRP Combinations
Livv Natural Editorial (2024). Livv Natural BlogCLink - CJC-1295 vs. Sermorelin: Which Peptide is Best
ThinWorks Editorial (2024). ThinWorks BlogCLink - Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women
["Khorram O","Laughlin GA","Yen SS"] (1997). Journal of Clinical Endocrinology & MetabolismCPMID:9141543DOI - Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men
["Corpas E","Harman SM","Pineyro MA","Roberson R","Blackman MR"] (1992). Journal of Clinical Endocrinology & MetabolismCPMID:1639946DOI - On the actions of the growth hormone-releasing hexapeptide, GHRP
["Bowers CY","Sartor AO","Reynolds GA","Badger TM"] (1991). EndocrinologyCPMID:2004615DOI - Growth hormone-releasing peptide (GHRP)
["Bowers CY"] (1998). Cell and Molecular Life SciencesCPMID:9465289DOI - Selective lack of growth hormone (GH) response to the GH-releasing peptide hexarelin in patients with GH-releasing hormone receptor deficiency
["Alba M","Fintini D","Salvatori R"] (1999). Journal of Clinical Endocrinology & MetabolismCPMID:10084578DOI - The safety and efficacy of growth hormone secretagogues
["Sigalos JT","Pastuszak AW"] (2018). Sexual Medicine ReviewsCPMID:28431257DOI - Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?
Prakash A, Croom J, et al. (2009). Clinical Interventions in Aging (PMC2699646)BPMID:19503774DOI - Determination That GEREF (Sermorelin Acetate) Injection Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
U.S. Food and Drug Administration (2013). Federal RegisterALink - The Benefits of Sermorelin Peptide for Hormonal Health and Wellness (citing 16-week lean mass study)
Huddle Men's Health Editorial (2024). Huddle Men's Health BlogCLink - Sermorelin – Wikipedia (Mechanism of Action and Molecular Structure)
Wikipedia Contributors (2024). WikipediaCLink - Sermorelin | Reviews, Clinical Trials, and Safety
Peptides.org Editorial (2024). Peptides.orgCLink - Sermorelin: Dosage, Benefits, Side Effects & Before and After (2026)
PeptideDeck Editorial (2026). PeptideDeck BlogCLink - Sermorelin Acetate Injection – Compounding Information
Empower Pharmacy (2024). Empower PharmacyCLink - Sermorelin Acetate (Sermorelin): Side Effects, Uses, Dosage, Interactions, Warnings
RxList Editorial (2024). RxListBLink
Community Sources
Storage
Unopened
Lyophilised powder: refrigerator (2–8 °C), protected from light; do not freeze prior to use.
Opened
After reconstitution with bacteriostatic water: refrigerator (2–8 °C), use within 14–28 days; do not freeze.
Notes
Reconstituted solution is stable at room temperature for short periods only (<4 h). Do not use if the solution is cloudy or particles are visible.